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Abstract
Background: Disseminated tumor cells (DTCs) can be detected using ultrasensitive immunocytochemical assays
and their presence in the bone marrow can predict the subsequent occurrence of overt metastasis formation and
metastatic relapse. Using expression profiling on early stage primary breast tumors, low IRX2 expression was
previously shown to be associated with the presence of DTCs in the bone marrow, suggesting a possible role of
IRX2 in the early steps of metastasis formation. The purpose of this study is to gain insights into the significance of
IRX2 protein function in the progression of breast cancer.
Methods: To assess the physiological relevance of IRX2 in breast cancer, we evaluated IRX2 expression in a large
breast cancer cohort (n = 1992). Additionally, constitutive IRX2 over expression was established in BT-549 and
Hs578T breast cancer cell lines. Subsequently we analyzed whether IRX2 overexpression effects chemokine
secretion and cellular motility of these cells.
Results: Low IRX2 mRNA expression was found to correlate with high tumor grade, positive lymph node status,
negative hormone receptor status, and basal type of primary breast tumors. Also in cell lines low IRX2 expression
was associated with mainly basal breast cancer cell lines. The functional studies show that overexpression of the
IRX2 transcription factor in basal cell lines suppressed secretion of the pro-metastatic chemokines and inhibited
cellular motility but did not influence cell proliferation.
Conclusion: Our results imply that the IRX2 transcription factor might represent a novel metastasis associated
protein that acts as a negative regulator of cellular motility and as a repressor of chemokine expression. Loss of
IRX2 expression could therefore contribute to early hematogenous dissemination of breast cancer by sustaining
chemokine secretion and enabling mobilization of tumor cells.
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Background
Metastasis - the main cause of cancer related deaths -
is a complex multi-step process [1]. A key event is
the systemic spread of single tumor cells from the
primary lesion through the blood circulation into dis-
tant organs. The presence of disseminated tumor cells
(DTC) in the bone marrow (BM) of cancer patients is
an independent predictor of metastatic relapse in
breast cancer and other solid tumors [2, 3]. Despite
progress in the classification of tumors and the iden-
tification and characterization of disseminated tumor
cells in BM of cancer patients [4], the early events of
the metastatic cascade, which leads to shedding of
single tumor cells from the primary tumor mass still
remains elusive.
The transcription factor Iroquois Homeobox 2 (IRX2)
is a member of the Iroquois homeobox gene family.
Members of this family appear to play multiple roles
during pattern formation of vertebrate development
[5–7]. In the breast tissue, IRX2 is expressed in ductal
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and lobular epithelium, but not in myoepithelium and
it is suggested to function in linage-specific epithelial
cell differentiation [8]. The relevance of the IRX2
transcription factor throughout cancer progression is
somewhat contradictory. Amplification of the IRX2
chromosomal locus on 5p15.33 has been identified in
breast and soft tissue sarcomas [9, 10]. In breast can-
cer this amplification may coexists with an activating
mutation of the PIK3CA gene [9]. In osteosarcomas
knockdown of IRX2 inhibits cell proliferation and in-
vasion [11], and elevated IRX2 expression is corre-
lated with worse outcome and age in infant acute
lymphoblastic leukemia [12]. Thus, these studies sug-
gest a possible oncogenic function for the IRX2 pro-
tein, especially in malignant cells of mesenchymal
origin. In contrast, other studies have shown that
hypermethylation of IRX2 promoter region frequently
occurs in lung squamous cell and adenocarcinomas
[13, 14]. Also one study showed that CpG islands in
the IRX2 gene were significantly more methylated in
luminal A in comparison to basal tumors [15]. Most
of these studies have not performed functional valid-
ation of the exact biological role of the IRX2 in
tumor progression. We have recently shown that low
IRX2 expression is associated with the presence of
DTCs in the bone marrow of breast cancer patients
[16], suggesting a possible role of IRX2 as a metasta-
sis suppressor protein in breast cancer.
Although many of the early events of tumor cell dis-
semination and metastasis formation remain unclear, dif-
ferent studies emphasize the importance of chemokines
in the microenvironment of the primary tumor and the
site of metastasis for cancer cell dissemination and
metastatic outgrowth [17]. For instance the expression
of the chemokine CCL5 (RANTES) can be correlated
with progressive disease in breast cancer [18] and bone
metastasis of breast cancer cells is depending on signaling
through the associated receptor CCR5 [19]. Coincidently
CCR5 antagonists block metastasis formation of the breast
cancer cell line MDA-MB-231 in mice, providing evidence
for a key role of CCL5/CCR5 in the invasiveness of basal
breast cancer cells [20]. Although accumulating evidence
emphasizes the central impact of chemokines on metasta-
sis formation in breast cancer [21, 22], the mechanism for
elevated levels of tumor cell derived chemokines secretion
remains poorly understood.
In this study, we aimed to validate the clinical import-
ance of IRX2 expression and to gain insights into the
significance of IRX2 expression in the progression of
breast cancer. The obtained data provide further evi-
dence for IRX2 as a potential metastasis suppressor as
ectopic IRX2 expression diminished secretion of differ-
ent chemokines and acts as negative regulator of cellular
motility of breast cancer cells.
Results
Expression of IRX2 in primary breast tumors
We previously found that low IRX2 gene expression in
primary breast tumors is associated with the presence of
DTCs in the bone marrow [16]. Low IRX2 was also asso-
ciated with shortened survival of breast cancer patients
in one analyzed breast cancer data set [16]. To further
investigate the patho-physiological relevance of IRX2
gene expression in breast cancer, we evaluated IRX2
gene expression in a large publically available patient co-
hort comprised of 1992 patients (Table 1). We found
that IRX2 is associated with several clinical prognostic
factors. Low IRX2 mRNA expression was found to be
correlated with high tumor stage (p = 0.004), high
tumor grade (p < 0.001) and the presence of lymph
node metastasis (p = 0.044). On the other hand, low
IRX2 mRNA expression was found to be significantly
correlated with low expression of both the estrogen
(p = 0.001) and the progesterone (p < 0.001) steroid re-
ceptors. Surprisingly, lower IRX2 mRNA expression
was also significantly correlated with smaller tumor
size (p = 0.05). Finally we found that high IRX2 ex-
pression is associated with the luminal A molecular
subtype and that low IRX2 expression is significantly
more frequent in tumors classified as basal and lu-
minal B (p < 0.001). Taken together these analyses
clearly show that low IRX2 expression is correlated
with different parameters of poor prognosis, indicat-
ing that loss of IRX2 expression is associated with
less differentiated and more aggressive breast tumors.
Nonetheless, no significant correlation between low
IRX2 expression and shortened survival was found in
this data set (data not shown).
Expression of IRX2 in breast cancer cell lines
To further investigate the significance of IRX2 expres-
sion in breast cancer, we evaluated IRX2 expression in a
panel of breast cancer cell lines. IRX2 mRNA expression
was detected in eight out of 11 breast cancer cell lines at
variable levels, as determined by quantitative real-time
PCR analysis (Fig. 1a). The IRX2 protein expression was
determined by Western blot analysis (Fig. 1b) in the
same set of cell lines using a custom-made IRX2-specific
polyclonal antibody. The level of IRX2 protein expres-
sion corresponds well with the level of IRX2 mRNA de-
tected in these cells. In line with a potential metastasis
suppressing function of IRX2, the poorly differentiated,
highly metastatic basal breast cancer cell lines MDA-
MB-231, Hs578T and BT-549 were completely negative
for IRX2 protein expression. IRX2 expression was found
in the luminal A cell lines (MCF7, CAMA-1, T-47D, ZR-
75-1 and KPL1) as well as in the HER2 over expressing
cell lines SKBR-3 and BT474. In BT-474 we found IRX2
transcript but no protein expression.
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Analysis of IRX2 regulated network
Existing functional studies have so far described the bio-
logical function of IRX2 mainly in the context of pattern
formation during embryonic development [5, 6]. To ob-
tain evidence about the biological function of the IRX2
transcription factor in breast epithelial cells and to iden-
tify genes that might represent direct transcriptional tar-
gets, we used SAM-analysis (Significance Analysis of
Microarrays) on a large published data set of breast can-
cer patients (GSE6532). Altogether 17 transcripts were
found significantly inversely correlated with IRX2 ex-
pression and 43 transcripts were concurrently upregu-
lated in patients with high IRX2 expression (Additional
file 1: Table S1). Gene ontology analysis [23] was carried
out on these 60 most correlated and inversely correlated
genes Interestingly, 6 out of 60 defined genes belonged
to “chemokine signaling pathway” (p-value: <0.001;
Benjamini: 0.001). Among the inversely correlated
genes were four chemokines, CCL5, CXCL9, CXCL10
and CXCL11 indicating that IRX2 might be actively
involved in the regulation of chemokine secretion by
mediating the transcriptional repression of these che-
mokines in breast cancer cells.
IRX2 protein expression represses chemokine secretion of
breast cancer cells
To experimentally validate the possible role of IRX2
as a metastasis suppressing protein and repressor of
migration and chemokine expression, we stably expressed
a c-terminal HA-tagged IRX2 protein in IRX2-deficient
BT-549 and Hs578t breast cancer cell lines. Successful
ectopic IRX2 protein expression in both cell lines was
validated by Western Blot analysis using a HA-specific
antibody (Fig. 2a).
To investigate whether ectopic IRX2 expression has an
influence on chemokine secretion, we analyzed condi-
tioned cell culture media from BT-549 and Hs578t cells
with a chemokine antibody array. In cell culture super-
natants taken from BT-549 cells we found differences in
the presence of CCL5, CXCL1, CXCL8 and CXCL11.
Remarkably, the expression of all four chemokines was
considerably lower in BT-549 cells overexpressing the
IRX2 protein confirming the potential role of IRX2 in
the control of chemokine expression (Fig. 2b/c). In cell
culture supernatants taken from Hs578t vector control
cells we found more CXCL7 expression in comparison
to supernatants taken form cells overexpressing IRX2
(Fig. 2b/c). Interestingly, we also found reduced expres-
sion of CCL5 in Hs578t cells overexpressing IRX2, tough
the overall expression of CCL5 was low abundant in
Hs578t cells.
Migration inhibitory activities of IRX2 in human breast
cancer cells
To further explore the possible role for IRX2 in tumor
progression, we investigated the ability of IRX2 expres-
sion to modify cell migration and proliferation of breast
Table 1 Analysis of IRX2 mRNA expression in primary breast
tumors. IRX2 expression was determined in one large published
expression data set [29] and correlated to the indicated clinico-
pathological parameters
IRX2 low IRX2 high P-value
n % n %
All patients 998 50.1 994 49.9 %
Histology <0.001
Ductal 809 82.7 744 76.5
Lobular 47 4.8 101 10.4
Ductolobular 42 4.3 48 4.9
Others 69 7.1 76 7.8
Tumor stage 0.004
1 174 31.8 198 39.4
2 308 56.2 271 53.9
3 + 4 66 12.1 34 6.8
Grade <0.001
1 59 6.2 111 11.7
2 352 36.9 423 44.7
3 544 57.0 413 43.6
Lymph node status 0.044
N0 503 50.4 546 54.9
N+ 495 49.6 448 45.1
Tumor size
<2 cm 407 43.3 499 45.8 0.050
>2 cm 578 58.7 532 54.2
ER expression 0.001
Negative 268 26.9 206 20.7
Positive 730 73.1 788 79.3
PR expression <0.001
Negative 540 54.1 403 40.5
Positive 458 45.9 591 59.5
HER2 expression 0.735
Negative 876 87.8 867 87.2
Positive 122 12.2 127 12.8
Subtype <0.001
Basal 206 20.7 125 12.6
HER2 121 12.2 119 12.0
LumA 303 30.5 418 42.2
LumB 292 29.3 200 20.2
P53 mutation status 0.454
Mutant 56 12.9 43 11.1
wt 378 87.1 343 88.9
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cancer cells. Migration of BT-549 cells was determined
by performing a wound healing (scratch) assay (Fig. 3a).
At 5 h, in the presence of 10 % FCS, vector-transduced
BT549 cells closed half of the wound, whereas BT-549
cells with ectopic IRX2 protein expression only closed
30 %. After 9.5 h vector transduced BT-549 cells closed
the entire wound whereas the IRX2 expressing cells
closed 58 % (P < 0.001). These results clearly show that
ectopic expression of IRX2 protein inhibits the migra-
tion of BT-549 cells. The difference was not caused by a
different proliferation rate as shown in Fig. 3b. We could
not detect any effect on cell proliferation in cells over
expressing the IRX2 protein.
Validation of chemokine transcript expression in cells
over expressing IRX2
To validate whether the IRX2 protein represses chemo-
kine expression in BT549 and Hs578T cells, we exam-
ined mRNA expression of the potential IRX2 targets
CCL5, CXCL1, CXCL7, CXCL8, CXCL9, CXCL10,
CXCL11 and CXCL16 by qPCR analysis (Fig. 4). CCL5,
CXCL8 and CXCL10 were found to be expressed in both
cell lines at abundant levels and, furthermore, we found
a concordant downregulation of all three chemokines in
the two cell lines that over express IRX2. CXCL16 was
also found to be expressed in both cell lines but IRX2
overexpression led only to a reduced CXCL16 expression
in BT-549 cells (Fig. 4). CXCL1 was found not to be
expressed in Hs578T cells, whereas CXCL1 mRNA ex-
pression could be detected in BT-549 cells and its ex-
pression is reduced in BT-549 cells over expressing
IRX2. CXCL7 was found not to be expressed in BT-549
cells, whereas CXCL7 mRNA expression was detected in
Hs578t cells. However, the qPCR analysis showed no sig-
nificant reduced CXCL7 expression in Hs578t cells over
expressing IRX2. CXCL9 and CXCL11 were not found to
be expressed in the two analyzed cell lines. We also in-
vestigate whether the IRX2 transcription factor has a dir-
ect effect on CCL5 promoter activity and conducted a
reporter gene assay using the proximal human CCL5
promoter fragment linked to the firefly luciferase gene.
Luciferase activity was also shown to be significantly
lower in presence of the IRX2 protein in BT-549 cells
(Additional file 2: Figure S1).
Fig. 1 Analysis of IRX2 mRNA and protein expression in breast cancer cell lines. a Quantitative gene expression analysis of IRX2 in different breast
cancer cell lines. The data shown are the average fold change normalized to RPLP0 and UHR expression of three independent experiments; the
error bars represent the standard deviation of the mean. b IRX2 protein expression in the same panel of human breast carcinoma cell lines was
determined by Western blot analysis using a polyclonal RAI2-specific antibody that recognizes an internal IRX2 epitope. Equal loading was
demonstrated using an antibody recognizing HSC70
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Validation of migration inhibitory activities of IRX2
As IRX2 suppresses the secretion of different chemo-
kines, we used the Boyden chamber assay to analyze the
effect of conditioned media obtained from either vector-
or IRX2-transduced BT-549 cells as a potential chemo-
attractant for parental BT-549 or MDA-MB-231 cells,
respectively. Both cell lines were seeded in starvation
medium into the upper chambers. The bottom wells
held conditioned medium from either vector- or IRX2-
transduced cells. After 24 h the number of migrated cells
was determined. Cell counts of migrated cells of both
cell lines were decreased when conditioned medium
from IRX2 expressing cells was used as chemoattractant.
These results demonstrate that IRX2 over expression
has a negative effect on autocrine stimulation of cellular
motility (Fig. 5a). We further analyzed the potential
Fig. 2 Analysis of IRX2 expression and chemokine secretion in breast cancer cell lines over expressing IRX2. a Recombinant IRX2 protein expression in
BT-549 and Hs578T cells that were transduced with retro-virus containing HA-tagged IRX2-cDNA. IRX2 protein expression was determined by Western
blot analysis using a HA-specific antibody. Equal loading was demonstrated using an antibody recognizing HSC70. b Results from Proteome Profiler
Antibody Array for determination of relative chemokine secretion. Cell culture supernatants from BT-549 and Hs578t cells over expressing the
IRX2 protein were analyzed and compared with the vector control supernatants. c Normalized pixel intensities from Proteome Profiler
Antibody Arrays. Individual signal intensities were measured using ImageJ software and normalized to the mean signal intensities of all
reference spots
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inhibitory effects of IRX2 over expression on migration
in a Boyden chamber assay. We seeded either vector- or
IRX2-transduced BT-549 cells into the upper chambers
and in the lower chamber DMEM containing 10 % FCS
was used as a chemoattractant. Also in this experiment,
the number migrated cells were significantly decreased
for cells expressing the IRX2 transcription factor in
comparison to vector control cells (Fig. 5b).
Discussion
In this study we sought to examine the significance of
IRX2 expression in the progression of breast cancer. In
our previous study we showed that a low IRX2 gene ex-
pression in early stage primary breast tumors is associ-
ated with the presence of DTCs in the bone marrow and
was also associated with shortened survival of breast
cancer patients in one analyzed breast cancer data set
[16], indicating a possible function of the IRX2 protein
as a metastasis suppressing protein. In contrast, it has
been reported that some breast cancers exhibit high
levels of IRX2 expression [9] and that an amplification
of the IRX2 genomic locus frequently coexist with an ac-
tivating mutation of the PIK3CA gene in breast cancer
[9], pointing also to a possible oncogenic function of the
IRX2 protein in cell proliferation. Furthermore, immu-
nohistochemical staining of 85 breast tumors showed ex-
pression of the IRX2 protein in cancerous breast tissue
and revealed a significant correlation of IRX2 protein ex-
pression only with tumor size, suggesting a possible
oncogenic function for the IRX2 protein in breast cancer
[9]. On the other hand, we found that high IRX2 mRNA
expression correlates with different parameters that de-
fine well differentiated breast tumors and good clinical
outcome, like positive hormone receptor status as well
as low tumor stage and grade. Also high IRX2 expres-
sion was found to be inversely correlated with lymph
node status, a known indicator of an unfavorable prog-
nosis. Taken together our results suggest that low IRX2
mRNA expression is a characteristic of tumors that have
acquired an aggressive phenotype. Thus, IRX2 could ex-
hibit dual functions in the progression of breast cancer,
i.e., in the early stages of tumor development elevated
IRX2 expression might contribute to tumor cell prolifer-
ation and transformation. This might also depend on
concomitant genetic lesions like the described activating
mutation of the PIK3CA [9]. On the contrary, at a more
Fig. 3 Analysis of cell migration and proliferation. a Migration analysis of BT-549 cells over expressing IRX2 and from control cells by wound healing
assay. Closure of wounded cell layer was examined by time-lapse videomicroscopy and evaluated using the Volocity 6 software. b Analysis of cell
proliferation of BT-549 cells over expressing IRX2 and control cell lines by MTT assay. Five thousand cells were plated in quadruplicates and incubated
under normal culture conditions for the indicated time span before measurement. Error bars represent the standard deviation of the mean of three
independent experiments
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advanced stage of tumor progression loss of IRX2 ex-
pression may contribute to tumor cell dissemination and
mobilization, as suggested by the previously described
association of low IRX2 expression in primary breast tu-
mors with positive DCT status in BM [16] and the here
described correlation to positive lymph node status.
The analysis of IRX2 mRNA and protein expression in
breast cancer cell lines showed that IRX2 expression is
absent in the highly aggressive MDA-MB-231, BT-549
and Hs578T cell lines that are all classified to belong to
the basal molecular subtype of breast cancer [24]. These
findings are in line with the clinical observation that
IRX2 expression is significantly lower in primary tumors
belonging to the more aggressive basal subtype. We ori-
ginally identified low IRX2 to be part of gene signature
associated with the presence of DTCs in the bone mar-
row in patients with luminal breast tumors [16]. How-
ever, as low IRX2 is in general associated with the basal
Fig. 4 Validation of mRNA expression of different chemokines in BT-549 and Hs578T cells over expressing IRX2. Quantitative gene expression analysis
of the indicated chemokines. The data shown are the average fold change normalized to RPLP0 and parental cell line expression of three independent
experiments; the error bars represent the standard deviation of the mean. P-values are calculated with the two-sided Student’s t-test (*, p < 0.05)
Fig. 5 Analysis of cell migration. a Migration analysis of parental BT-549 and MDA-MB-231 cells using Boyden chamber assay. Cell culture supernatants
from BT-549 cells over expressing IRX2 or from control cell lines were used as chemoattractant for 24 h. Error bars represent the standard deviation of
the mean of three independent experiments done in triplicates. P-values were calculated by the two-sided Student’s t-test (*, p < 0.05). b Migration
analysis of BT-549 cells over expressing IRX2 and from control cells using Boyden chamber assay Standard cell culture medium was used
as chemoattractant for 24 h. Error bars represent the standard deviation of the mean of three independent experiments done in triplicates. P-values
were calculated by the two-sided Student’s t-test (*, p < 0.05)
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subtype of breast cancer, our results indicate that our
DTC signature including low IRX2 expression obtained
from luminal breast cancer patients defines a more ag-
gressive subpopulation within the luminal group associ-
ated with more aggressive traits. Furthermore, as in this
study we found a significant correlation between IRX2
and ESR1 expression we therefore assume that IRX2
might function in determining luminal cell differenti-
ation as suggested by other scientists [8].
The biological role of the transcription factor IRX2 in
breast epithelial cells is poorly defined and direct tran-
scriptional targets in breast epithelial cells have not been
described. We identified several genes whose expression
is either positively or inversely correlated with IRX2
mRNA expression. We found that in particular the ex-
pression of several chemokines is inversely correlated
with IRX2 expression in breast tumors. To experimen-
tally validate the possible role of IRX2 as a metastasis
suppressing protein, we initially aimed to study the po-
tential involvement of the IRX2 transcription factor in
breast cancer progression using a RNA interference me-
diated experimental approach. In our hands neither
transfection of small interfering RNAs nor viral trans-
duction of shRNAs yielded a convenient reduction of
IRX2 protein expression in breast cancer cell lines,
which has already been reported by other researchers
[9]. Therefore, we rather stably expressed a c-terminal
HA-tagged IRX2 protein in IRX2-deficient BT-549 and
Hs578t breast cancer cell lines of basal subtype. Overex-
pression of the IRX2 transcription factor in BT-549 and
Hs578T breast cancer cells leads to concordant repres-
sion of CCL5, CXCL8 and CXCL10 mRNA expression.
CCL5 and CXCL8 were also found to be secreted at
reduced levels by BT-549 cells following ectopic IRX2
expression. Elevated levels of CCL5 in plasma and at the
primary tumor site of breast cancer patients have been
previously associated with progressive and more ad-
vanced disease [25] and with axillary lymph node metas-
tasis [26]. Also CXCL8 is overexpressed in invasive
breast cancer cells [27] and is believed to play a signifi-
cant role in the progression of breast cancer [28]. Taken
together, these findings suggest that the activity of the
IRX2 protein in breast cancer cells might be associated
with the control of chemokine expression and that a
loss of IRX2 expression in tumor cells might lead to
augmented chemokine secretion, which supports
mobilization and increases invasiveness of tumor cells.
However, it remains unclear if the IRX2 transcription
factor is directly involved in the transcriptional regu-
lation of the herein identified chemokines or whether
the observed reduced chemokine expression is a sec-
ondary effect of IRX2 overexpression. Further studies
that also encompasses exact mapping of IRX2 binding
sites, are needed to unravel the exact mechanism
behind the observed IRX2 mediated down regulation
of chemokine expression.
In line with the suggestion that loss of IRX2 expres-
sion might contribute to the onset of tumor cell dissem-
ination, we could show that over expressing of IRX2
markedly reduced the motility of breast cancer cells but
did not influence cell proliferation. Conditioned media
obtained from IRX2 over expressing BT-549 cells is less
effective as a chemoattractant than medium from con-
trol cells. In addition, when 10 % FCS was used as
chemoattractant, we also found that forced IRX2 expres-
sion impedes cellular motility independent from the
presence of chemokines in conditioned media and most
significant results were obtained from the scratch assays.
We thus assume that the observed reduction of motility
in course of IRX2 overexpression in different assays is
based on the generic reduction of chemokines as well as
on pleiotropic effects of IRX2 overexpression that still
needs to be specified in future studies. Yet, much re-
search remains, including in vivo experiments, to obtain
a better understanding of the potential role of the IRX2
transcription factor in the metastatic cascade.
Conclusion
The obtained results show that low expression of the
IRX2 transcription factor occurs mainly in less differen-
tiated, basal breast tumors. We furthermore found that
the IRX2 protein inhibits cellular motility of breast can-
cer cells, supporting the presumptive metastasis sup-
pressing function of the IRX2 protein. In addition, we
were able to show that IRX2 over expression represses
the secretion of different pro-metastatic chemokines.
The loss of IRX2 expression at the primary tumor might
therefore contribute to bone metastasis formation by
mobilizing cells and rendering them for dissemination.
Methods
In silico validation
For in-silico validation the METABRIC gene expression
data set consisting of expression results from 1992 breast
cancer patients were retrieved from the European
Genome-phenome Archive (EGAS00000000083, [29]).
Gene expression data on Affymetrix platforms were proc-
essed using custom CDF that re-map probes to
ENSEMBL transcripts. Using the appropriately pre-
processed gene expression values, samples were separated
into high-expression and low expression groups at the
median and correlated with different clinico-pathological
factors provided with gene expression information. A sec-
ond data set (GEO accession no. GSE6532) [30] consisting
of 262 hormone receptor positive and 45 hormone recep-
tor negative breast cancer patients was used to investigate,
which genes expression are exhibited correltaed with the
IRX2 expression. The dataset was quantile normalized
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and subsequently genes differentially expressed between
the extreme tertials of IRX2 expression were identified
using the significance analysis of microarrays (SAM) algo-
rithm with a false discovery rate (FDR) of 5 % and with
1000× repeated permutation [31]. To narrow down the re-
sults, in a second, step only transcripts with a fold
change > 2 were taken into account.
Quantitative real-time PCR analysis
qPCR analyses for the patients samples were performed on
150 ng total RNA isolated by RNeasy Micro Kit (Qiagen).
For cell line analyses 500 ng total RNA was transcribed
using First Strand cDNA Synthesis Kit (Fermentas St.
Leon-Rot, Germany) together with 500 ng of universal
human reference (UHR, Stratagene, Agilent technologies,
Texas USA). Quantitative real-time PCR analyses were
performed on Eppendorf Master Cycler using SYBR
Green (Fermentas, St. Leon-Rot, Germany) as fluores-














The analyses were performed in triplicates and the mean
values were used for each gene. The mRNA levels were
normalized to the mRNA level of the ribosomal RPLP0
gene using ΔΔCT-method for quantification. The results,
expressed as N-fold differences in target gene expression
compared to universal human reference (UHR) or paren-
tal cell line expression.
Cell culture
MDA-MD-231 and SK-BR-3 cells were obtained from
ATCC. BT-549, BT-474, T-47D, ZR-75-1 and MDA-
MD-468 cells were obtained from Cell Lines Service
(Heidelberg). MCF-7 and Hs578T were a friendly gift
from Dr. Steven Johnsen (University of Göttingen,
Germany). Phoenix amphotropic retroviral packaging
cells were a friendly gift from Dr. Volker Assmann
(UKE, Hamburg, Germany). CAMA-1 and KPL-1 cells
were a friendly gift from Dr K. Iljin (VTT, Espoo, Finland).
Cells were grown as monolayers according to standard con-
ditions in either DMEM or RPMI supplemented with 10 %
fetal calf serum and 2 mM L-glutamine (Invitrogen)
at 37 °C in a humidified atmosphere containing 10 %
CO2 or 5 % CO2 respectively. Analysis of cellular
viability was done by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. 5000 cells
were plated in quadruplicates and absorbance at 570 nm
was measured after 3 h treatment with MTT solution and
lysis of cells in isopropanol containing 4 mM HCl and
0.1 % (w/v) NP-40. Lysates were additionally treated with
sonicator to achieve complete lysis of cells.
Expression plasmids and viral transduction
IRX2 coding sequence was amplified (forward-primer:
CCGCTGCTCGGCGTGACGCG, reverse-primer: TAG
GTAGGGCTGGACGCCC) from cDNA obtained from
the breast cancer cell line MCF-7 and cloned into the
expression plasmid phCMV3 (Genlantis) using EcoRI
and KpNI restrictions sites. HA-tagged IRX2 cDNA se-
quence was reamplified and cloned into the retroviral
expression plasmid pMXs-IRES-Puro (Cell Biolabs) using
EcoRI and NotI restrictions sites and afterwards the cloned
cDNA sequence was verified by sequencing. For production
of retroviral particles ψNX-ampho cells were transfected
with the retroviral expression plasmid using Lipofectamine
2000 (Invitrogen) according to manufacturer’s suggested
protocol. Viral transduction was done with 500 μl viral
supernatant added to 50 % confluent recipient cultures in
6-well plates containing 1 ml cell culture medium. Positive
selection was achieved 24 h after transduction using
puromycin-containing medium (2 μg/ml, Sigma-Aldrich).
Cells were subsequently kept under puromycin for 4 days.
Western blot analysis and antibody production
Whole cell extracts from cultured cells were prepared by
direct lysis and sonication of cells in SDS sample buffer
containing proteinase and phosphatase inhibitors. Cell
extracts were separated on denaturing 8 % polyacryl-
amide gels and blotted onto PVDF membrane. Detection
of IRX2 protein was either done by incubation with an
HA specific antibody (Sigma-Aldrich, H6908) or a cus-
tom made IRX2 specific antibody. Detection of the
HSC70 protein (Santa Cruz, clone B6) was used as load-
ing control. To generate polyclonal antibodies against
IRX2, a peptide DDEDDDEEGERGLAPPKPVTSS corre-
sponding to the central region of human IRX2 was syn-
thesized, coupled to keyhole limpet hemocyanin and was
then injected into rabbits. IRX2 specific antibodies were
isolated by immunoaffinity purification using the corre-
sponding immunizing peptide coupled to a solid sup-
port. Reactivity and specificity of the IRX2 specific
antibody was verified by Western blot analysis.
Chemokine antibody array
Conditioned medium from confluent BT-549 and
Hs578t cells stably expressing either IRX2 or empty vec-
tor were tested for chemokine secretion by chemokine
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antibody array following the manufacturer’s instructions
(R&D Systems Proteome Profiler™ Human Chemokine
Array Kit). Estimation of normalized signal intensity was
done using ImageJ software.
In vitro scratch assay
BT-549 cells which were either transduced with IRX2 or
empty vector containing retrovirus were plated in a con-
centration of of 7 × 105 cells and grown to confluence in
6 well plates under standard culture conditions. After-
wards cells were incubated for 24 h in DMEM contain-
ing 0.5 % FCS. In vitro scratch assay was performed as
described elsewhere [32]. Cell movement was recorded
in real time using an Improvision Live Cell Spinning
Disk Microscope and data analysis was done using the
Volocity® software (Perkin Elmer).
Transwell migration assay
5 × 104 BT-549 or MDA-MB-231 cells were plated in
serum-free DMEM media into the upper chambers of
BD Cell Culture Inserts for 24-well plates with 8.0 μm
pores (BD Falcon™). In the lower chamber conditioned
medium from confluent BT-549 cells stably expressing
either IRX2 or empty vector were used as chemoattract-
ant. Plates were incubated at 37 °C, and migration was
allowed to proceed for 20 h. Afterwards non migrated
cells in the upper chambers were removed with cotton
swabs, and the remaining cells were fixed in 4 % parafor-
maldehyde and stained with crystal violet. Cells were
counted by using a Zeiss light microscope. Four fields
were counted on each of two filters. Results are expressed
as average cells per field.
Ethical approval
Since all analyses were conducted on previously pub-
lished expression data from breast cancer patients or on
cell lines, no further ethics approval was required for
this study.
Additional files
Additional file 1: Table S1. Genes in primary breast tumors showing
exhibited correlation with IRX2 expression and functional annotation of
these genes. SAM-analysis (Significance Analysis of Microarrays) on and
functional annotation was used on a large published data set of breast
cancer patients (GSE6532). (XLS 79 kb)
Additional file 2: Figure S1. Gene reporter assay with reporter plasmid
containing proximal CCL5 promoter fragment. The reporter plasmid was
transfected into BT-549 cells that over express IRX2 and into the control
cell line. For normalization, a co-transfection with the pGL4.74 plasmid
containing the Renilla luciferase was performed. Each experiment was
performed in triplicate. Error bars represent the standard deviation of the
mean. (PDF 18 kb)
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